NS Healthcare is using cookies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
SECTOR: Patient Care
EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecular genetic diagnostics. The company’s portfolio encompasses indirect immunofluorescence assays (IFA), ELISAs, immunoblots, radioimmunoassays, chemiluminescence immunoassays (ChLIA) and molecular genetic test systems and spans over a thousand diagnostic parameters. State-of-the-art instruments and software provide efficient automation of analyses, increasing productivity and reliability in routine diagnostics. EUROIMMUN commands extensive know-how and a broad technology base allowing in-house research, development and production to optimally meet our customers’ needs.
EUROIMMUN AG
Seekamp 31, 23560 Luebeck
Germany
Tel. +49 451 2032-0
Fax: +49 451 2032-100
URL: www.euroimmun.com
Invasive aspergillosis (IA) is a life-threatening mycosis with a high morbidity and mortality rate in immunocompromised patients. A newly developed enzyme-linked immunosorbent assay from EUROIMMUN allows for the quantitative detection of Aspergillus antigen in patient serum or lung fluid samples, supporting early diagnosis of IA. With the option of semi-automated processing, it is especially suitable for high-throughput IA diagnostics in high-risk patients.
Download White PaperDetermination of anti-SARS-CoV-2 antibodies plays an important role in Covid-19 diagnostics and epidemiological studies. EUROIMMUN’s use of dried blood spots as sample material reduces the blood collection to a quick prick in the fingertip, sparing patients the burden of venous blood collection and streamlining IgG antibody screening.
Download White PaperIn-depth analysis of immune responses to SARS-CoV-2 is essential for vaccine development and optimisation of immunisation strategies. A trio of new assays from EUROIMMUN for quantification of anti-S1/receptor binding domain IgG antibodies, detection of neutralising antibodies targeting S1/RBD, and analysis of specific T-cell responses supports the differentiated investigation of SARSCoV- 2-specific immune responses.
Download White PaperA powerful trio of CE-marked tests from EUROIMMUN enables comprehensive investigation of immune responses to SARS-CoV-2 following vaccination or infection. The analysis encompasses quantitative measurement of anti-S1/RBD IgG antibodies, determination of the neutralising effect of these antibodies and analysis of SARS-CoV-2-reactive T cells.
Download White PaperThe UNIQO 160 allows labs to perform fast, high-quality image capture and analysis to deliver timely, more reliable results
